{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:13:43Z","timestamp":1779113623332,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109105","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:10:38Z","timestamp":1779109838000},"source":"Crossref","is-referenced-by-count":0,"title":["Anaplastic Thyroid Carcinoma With Cardiac Dysfunction Developed During Combination Therapy With Dabrafenib and Trametinib"],"prefix":"10.7759","author":[{"given":"Sorane","family":"Maezumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoaki","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge RC","year":"2010","unstructured":"Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010, 22:486-97. 10.1016\/j.clon.2010.03.013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-003-2737-6","article-title":"Prognostic factors of anaplastic thyroid carcinoma","volume":"34","author":"Kihara M","year":"2004","unstructured":"Kihara M, Miyauchi A, Yamauchi A, Yokomise H. Prognostic factors of anaplastic thyroid carcinoma. Surg Today. 2004, 34:394-8. 10.1007\/s00595-003-2737-6","journal-title":"Surg Today"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.920857","article-title":"Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis","volume":"13","author":"Huang D","year":"2022","unstructured":"Huang D, Zhang J, Zheng X, Gao M. Efficacy and safety of lenvatinib in anaplastic thyroid carcinoma: a meta-analysis. Front Endocrinol (Lausanne). 2022, 13:920857. 10.3389\/fendo.2022.920857","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022, 33:406-15. 10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0547","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara M","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H, et al.. A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid. 2024, 34:467-76. 10.1089\/thy.2023.0547","journal-title":"Thyroid"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK Inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu RI","year":"2019","unstructured":"Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, Totzeck M. Cardiovascular adverse events associated with BRAF and MEK Inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019, 2:e198890. 10.1001\/jamanetworkopen.2019.8890","journal-title":"JAMA Netw Open"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al.. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015, 372:30-9. 10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0072","article-title":"The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study","volume":"26","author":"Onoda N","year":"2016","unstructured":"Onoda N, Sugino K, Higashiyama T, et al.. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid. 2016, 26:1293-9. 10.1089\/thy.2016.0072","journal-title":"Thyroid"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0557","article-title":"A phase II study of the safety and efficacy of\u00a0lenvatinib in patients with advanced thyroid\u00a0cancer","volume":"15","author":"Takahashi S","year":"2019","unstructured":"Takahashi S, Kiyota N, Yamazaki T, et al.. A phase II study of the safety and efficacy of\u00a0lenvatinib in patients with advanced thyroid\u00a0cancer. Future Oncol. 2019, 15:717-26. 10.2217\/fon-2018-0557","journal-title":"Future Oncol"},{"key":"ref10","unstructured":"NCCN Guidelines. (2025). Accessed. April 3, 2026: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1470."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas ME","year":"2015","unstructured":"Cabanillas ME, Schlumberger M, Jarzab B, et al.. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015, 121:2749-56. 10.1002\/cncr.29395","journal-title":"Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2482-13-S2-S44","article-title":"Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review","volume":"13","author":"Guerra A","year":"2013","unstructured":"Guerra A, Di Crescenzo V, Garzi A, et al.. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. 2013, 13:S44. 10.1186\/1471-2482-13-S2-S44","journal-title":"BMC Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ23-0342","article-title":"The frequency of mutations in advanced thyroid cancer in Japan: a single-center study","volume":"71","author":"Toda S","year":"2024","unstructured":"Toda S, Iwasaki H, Okubo Y, et al.. The frequency of mutations in advanced thyroid cancer in Japan: a single-center study. Endocr J. 2024, 71:31-7. 10.1507\/endocrj.EJ23-0342","journal-title":"Endocr J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/genes10090709","article-title":"Molecular alterations in thyroid cancer: from bench to clinical practice","volume":"10","author":"Tirr\u00f2 E","year":"2019","unstructured":"Tirr\u00f2 E, Martorana F, Romano C, et al.. Molecular alterations in thyroid cancer: from bench to clinical practice. Genes (Basel). 2019, 10:709. 10.3390\/genes10090709","journal-title":"Genes (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1215697","article-title":"BRAF V600E inhibition in anaplastic thyroid cancer","volume":"368","author":"Rosove MH","year":"2013","unstructured":"Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013, 368:684-5. 10.1056\/NEJMc1215697","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman DM","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, et al.. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015, 373:726-36. 10.1056\/NEJMoa1502309","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0531","article-title":"Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas","volume":"3","author":"Montero-Conde C","year":"2013","unstructured":"Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al.. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013, 3:520-33. 10.1158\/2159-8290.CD-12-0531","journal-title":"Cancer Discov"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404357111","article-title":"p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer","volume":"111","author":"McFadden DG","year":"2014","unstructured":"McFadden DG, Vernon A, Santiago PM, et al.. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014, 111:E1600-9. 10.1073\/pnas.1404357111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah V","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al.. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023, 29:1103-12. 10.1038\/s41591-023-02321-8","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks M","year":"2017","unstructured":"Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol. 2017, 17:487-93. 10.1007\/s12012-017-9425-z","journal-title":"Cardiovasc Toxicol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/483498-anaplastic-thyroid-carcinoma-with-cardiac-dysfunction-developed-during-combination-therapy-with-dabrafenib-and-trametinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:10:41Z","timestamp":1779109841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/483498-anaplastic-thyroid-carcinoma-with-cardiac-dysfunction-developed-during-combination-therapy-with-dabrafenib-and-trametinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.109105","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}